Asymptomatic chronic gastrointestinal blood loss in patients taking aspirin or warfarin for cardiovascular disease

American Journal of Medicine

Volumn 100, Issue 6, 1996, Pages 598-604

  Greenberg, Paul D ^a   Cello, John P ^a   Rockey, Don C ^a  

^a SAN FRANCISCO GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; WARFARIN;

ADULT; ANTICOAGULATION; ARTICLE; BLEEDING; CARDIOVASCULAR DISEASE; CAUSE OF DEATH; CORONARY ARTERY DISEASE; FECES ANALYSIS; HEMOGLOBIN ANALYSIS; HUMAN; MAJOR CLINICAL STUDY; OCCULT BLOOD; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR;

EID: 0030175833     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9343(96)00009-5     Document Type: Article

References (19)

1. 1. ISIS-2 Collaborative Group. Randomized trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. Lancet. 1988;318:349-360.
2. 2. The RISC Group. Risk of myocardial infarction and death during treatment with low dose aspirin and intravenous heparin in men with unstable coronary artery disease. Lancet. 1990;336:827-830.
3. 3. Veterans Administration Cooperative Study. Protective effects of aspirin against acute myocardial infarction and death in men with unstable angina. NEJM. 1983;309:396-403.
4. 4. Wallentin LC, the Research Group on Instability in Coronary Artery Disease in Southeast Sweden. Aspirin (75 mg/day) after an episode of unstable coronary artery disease: long-term effects on the risk for myocardial infarction, occurrence of severe angina and the need for revascularization. J Am Coll Cardiol. 1991;18:1587-1593.
5. 5. Smith P, Arnesen H, Holme I. The effect of warfarin on mortality and reinfarction after myocardial infarction. NEJM. 1990;323:147-152.
6. 6. Steering Committee of the Physicians' Health Study Research Group. Final report on the aspirin component of the ongoing physicians' health study. NEJM. 1989;321:129-135.
7. 7. Meade TW. Low-dose warfarin and low-dose aspirin in the primary prevention of ischemic heart disease. Am J Cardiol. 1990;65:7C-11C.
8. 8. Aspirin Myocardial Infarction Study Research Group. A randomized, controlled trial of aspirin in persons recovered from myocardial infarction. JAMA. 1980;243:661-669.
9. 9. The SALT Collaborative Group. Swedish aspirin low-dose trial (salt) of 75 mg aspirin as secondary prophylaxis after cerebrovascular ischaemic events. Lancet. 1991;338:1345-1349.
10. 10. Prichard PJ, Kitchingman GK, Walt RP, et al. Human gastric mucosal bleeding induced by low dose aspirin, but not warfarin. BMJ. 1989;298:493-496.
11. 11. Savon JJ, Allen ML, DiMarino AJ, et al. Gastrointestinal blood loss with low dose (325 mg) plain and enteric-coated aspirin administration. Am J Gastroenterol. 1995;90:581-585.
12. 12. Ahlquist DA, McGill DB, Schwartz S, et al. Fecal blood levels in health and disease. NEJM. 1985;312:1422-1428.
13. 13. Ahlquist DA, McGill DB, Schwartz S, et al. HemoQuant, a new quantitative assay for fecal hemoglobin. Ann Intern Med. 1984;101:297-302.
14. 14. Lynch NM, McHutchison JG, Young GP, et al. Gastrointestinal blood loss from a new buffered aspirin (ostoprin): measurement by radiochromium and HemoQuant techniques. Aust NZ J Med. 1989;19:89-96.
15. 15. Verheugt FWA, Laarse AVD, Funke-Kpper AJ, et al. Effects of early intervention with low-dose aspirin (100 mg) on infarct size, reinfarction and mortality in anterior wall acute myocardial infarction. Am J Cardiol. 1990;66:267-270.
16. 16. UK-TIA Study Group. The United Kingdom transient ischaemic attack (uk-tia) aspirin trial: final results. J Neurol Neurosurg Psychiatry. 1991;54:1044-1054.
17. 17. Antiplatelet Trialists' Collaboration. Secondary prevention of vascular disease by prolonged antiplatelet treatment. BMJ. 1988;296:320-331.
18. 18. Schwartz S, Dahl J, Ellefson M, and Ahlquist D. The "HemoQuant" Test: a specific and quantitative determination of heme (hemoglobin) in feces and other materials. Clin Chem. 1983;29:2061-207.
19. 19. St. John DJB, Young GP, McHutchison JG, et al. Comparison of the specificity and sensitivity of hemoccult and HemoQuant in screening for colorectal neoplasia. Ann Intern Med. 1992;117:376-382.